InsiderSignal.AI

InsiderSignal.ai

IONS - Ionis Pharmaceuticals Inc

Insider Sale by Baroldi Joseph (EVP, Chief Business Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Baroldi Joseph, serving as EVP, Chief Business Officer at Ionis Pharmaceuticals Inc (IONS), sold 1,626 shares at $71.79 per share, for a total transaction value of $116,727.00. Following this transaction, Baroldi Joseph now holds 49,256 shares of IONS.

This sale represents a 3.00% decrease in Baroldi Joseph's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, April 28, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 30, 2026, 2 days after the trade was made.

Ionis Pharmaceuticals Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Baroldi Joseph

EVP, Chief Business Officer

Joseph T. Baroldi is the Executive Vice President and Chief Business Officer at Ionis Pharmaceuticals, a position he has worked toward through progressive advancement within the company[[1]](https://theorg.com/org/ionis-pharmaceuticals/org-chart/joseph-t-baroldi). He began his career as a Research Associate at Ionis before advancing to Vice President of Business Development and Alliance Management, demonstrating significant growth within the organization[[1]](https://theorg.com/org/ionis-pharmaceuticals/org-chart/joseph-t-baroldi). Baroldi holds a Bachelor of Science degree in Biology from UC Irvine and an MBA from the University of California, San Diego[[1]](https://theorg.com/org/ionis-pharmaceuticals/org-chart/joseph-t-baroldi). Prior to his current role, he served as Chief Operating Officer at Avidity Biosciences, Inc., bringing external experience in the biotechnology sector[[1]](https://theorg.com/org/ionis-pharmaceuticals/org-chart/joseph-t-baroldi). In his capacity as EVP and Chief Business Officer at Ionis Pharmaceuticals, Baroldi is actively involved in the company's strategic direction during a period of significant growth[[2]](https://www.investing.com/news/insider-trading-news/ionis-pharma-evp-baroldi-sells-439k-in-shares-93CH-4480525). As of early 2026, he directly owns 45,413 shares of Ionis common stock and indirectly owns 4,772 shares through his spouse[[2]](https://www.investing.com/news/insider-trading-news/ionis-pharma-evp-baroldi-sells-439k-in-shares-93CH-4480525). Recent insider trading activity shows Baroldi exercising stock options and conducting share sales under Rule 10b5-1 trading plans, including a sale of 4,096 directly owned shares at $79.36 per share in March 2026[[4]](https://www.stocktitan.net/sec-filings/IONS/form-4-ionis-pharmaceuticals-inc-insider-trading-activity-f390e9fd6e13.html). His financial stake and ongoing involvement reflect his commitment to the company's success in an evolving pharmaceutical landscape.

View full insider profile →

Trade Price

$71.79

Quantity

1,626

Total Value

$116,727.00

Shares Owned

49,256

Trade Date

Tuesday, April 28, 2026

3 days ago

SEC Filing Date

Thursday, April 30, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

Discussion

Sign in to join the discussion.
Loading comments…
View news mentioning IONS

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/6080160

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime